Keyword: EuroBiotech Report
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.
The Big Biotech participated in the round to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.
Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
In this week's EuroBiotech Report, U.K. sector deal fizzles as hype hits reality, Idorsia gets $230 million, Cellectis names CMO and more.
In our EuroBiotech roundup this week, Atox raises $30 million, Bluebird inks CAR-T deal and Advicenne IPO raises €27 million.
The document details planned investments from drug developers including GlaxoSmithKline, although many of the commitments are vague or already known.
Cellectis has named Stéphane Depil, M.D., Ph.D., as its CMO and senior vice president of R&D.
The fund will reportedly embark on the spending spree while shifting a “significant” chunk of its operations from the U.S. to the U.K.
In this week's EuroBiotech Report, Merck bets on post-Brexit Britain, Innate rocked by lirilumab setback, UCL inks gene therapy pact and more.
In our EuroBiotech roundup this week, Orchard expands in U.S., analysts talk up Genmab buyout and Symphogen pockets Genentech milestone.